- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02284971
Pilot Study of SBRT and CDX-1127 in Prostate Cancer (Prostate-04)
A Pilot Study to Assess the Combination of Stereotactic Body Radiation Therapy and CDX-1127 in Modulating Local and Systemic T-cell Responses Against Prostate Cancer
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 1
Kontakte und Standorte
Studienorte
-
-
Virginia
-
Charlottesville, Virginia, Vereinigte Staaten, 22908
- University of Virginia
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
MAIN INCLUSION CRITERIA
Males, Age ≥ 18 years.
Participants must have histologically-proven prostrate adenocarcinoma that is castrate-resistant. Progressive disease is defined by one or more of the following:
- A rise in PSA on two successive determinations at least one week apart and PSA level ≥2ng/ml.
- Soft-tissue progression defined by RECIST 1.1.
- Bone disease progression defined by PCWG2 with two or more new lesions on bone scan.
Patients must have castrate levels of testosterone (<50 ng/dl [1.74 nmol/l]).
Patients must have undergone orchiectomy, or have been on LHRH agonists or antagonists, for at least 3 months prior to drug initiation. Patients on LHRH agonists/antagonists must remain on these agents for the duration of the study.
Clinical metastases must be present and confirmed on imaging studies.
Participants for whom radiation therapy is recommended for the prostate gland (or prostate bed nodule) and/or bone or soft tissue metastases.
SBRT may be administered to 1-4 sites and the treatment sites can include prostate gland (or prostate bed nodule for post-prostatectomy patients), bone metastases, and soft tissue metastases. Participants must have at least one site of disease that will be both irradiated with SBRT and biopsied to evaluate immunological outcomes.
ECOG performance status 0-2.
Adequate hepatic and renal function.
MAIN EXCLUSION CRITERIA
Prior malignancies, that will affect the completion and interpretation of the study.
Patients with active CNS metastases from prostate cancer.
Patients who are currently receiving systemic cytotoxic chemotherapy, radiation, or other experimental therapy, or who have received this therapy within the preceding 4 weeks. Patients who are currently receiving nitrosoureas or who have received this therapy within the preceding 6 weeks are excluded.
Patients who are currently receiving systemic cytotoxic chemotherapy, radiation, or other experimental therapy, or who have received this therapy within the preceding 4 weeks.
Major surgery within 4 weeks prior to the start of study treatment.
Patients who are receiving or have previously been treated CDX-1127.
HIV positivity
Evidence of active Hepatitis B virus or Hepatitis C virus.
Patients receiving the following medications at study entry or within the preceding 4 weeks (or longer, if otherwise specified) are excluded:
- Checkpoint inhibitors (within the preceding12 weeks)
- Allergy desensitization injections
- Systemic corticosteroids of more than 10 mg per day of prednisone (or equivalent), administered parenterally or orally, except for physiologic replacement. Inhaled steroids (e.g. Advair®, Flovent®, Azmacort®) are not permitted. Topical corticosteroids are acceptable, including steroids with very low solubility administered nasally for local effects only (e.g. Nasonex®)
- Any growth factors (e.g. GM-CSF, G-CSF, erythropoietin).
- Interferon or interleukin therapy
- Other Agents with putative immunomodulating activity. (e.g. sipuleucel-T (Provenge ®))
Other investigational drugs or investigational therapy if the patient is currently taking those drugs/therapy, or if they have received the drugs/therapy within 4 weeks prior to the start of study treatment.
Participants must not have had prior autoimmune disorders requiring cytotoxic or immunosuppressive therapy, or autoimmune disorders with visceral involvement.
Significant cardiovascular disease.
Active bleeding disorders or evidence of chronic or acute disseminated intravascular coagulation (DIC).
Concomitant therapeutic anticoagulation (i.e., warfarin) for reasons other than venous catheter patency.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Arm A: CDX1127 & SBRT Concurrent
SBRT will be administered to the primary tumor and/or site of metastatic disease over a period of 5 days (Days 1-5) at a constant dose for 1-4 sites of prostate cancer involvement:30 Gy in 5 fractions of 6 Gy each for prostate gland; 25 Gy in 5 fractions for bone and/or soft tissue metastases). Subjects will receive four doses of CDX-1127(3 mg/kg) (Days 1, 43, 64, 85). The study drug will be administered intravenously over a 90-minute time period and will be followed by a 2-hour observation period. A subject's dose of CDX-1127 will be calculated based on their actual body weight at the time of screening. A subject's dose of CDX-1127 will remain constant at each time point, unless they experience a greater than 10% change in body weight. |
Andere Namen:
|
Experimental: Arm B: CDX1127 & SBRT Sequential; CDX1127 upfront
SBRT will be administered to the primary tumor and/or sites of metastatic disease over a period of 5 days (Days 22-26) at a constant dose for 1-4 sites of prostate cancer involvement:30 Gy in 5 fractions of 6 Gy each for prostate gland; 25 Gy in 5 fractions for bone and/or soft tissue metastases). Subjects will receive four doses of CDX-1127(3 mg/kg) (Days 1, 43, 64, 85). The study drug will be administered intravenously over a 90-minute time period and will be followed by a 2-hour observation period. A subject's dose of CDX-1127 will be calculated based on their actual body weight at the time of screening. A subject's dose of CDX-1127 will remain constant at each time point, unless they experience a greater than 10% change in body weight. |
Andere Namen:
|
Experimental: Arm C: CDX1127 & SBRT Sequential; SBRT upfront
SBRT will be administered to the primary tumor and/or sites of metastatic disease over a period of 5 days (Days 1-5) at a constant dose for 1-4 sites of prostate cancer involvement:30 Gy in 5 fractions of 6 Gy each for prostate gland; 25 Gy in 5 fractions for bone and/or soft tissue metastases). Subjects will receive four doses of CDX-1127(3 mg/kg) (Days 22, 43, 64, 85). The study drug will be administered intravenously over a 90-minute time period and will be followed by a 2-hour observation period. A subject's dose of CDX-1127 will be calculated based on their actual body weight at the time of screening. A subject's dose of CDX-1127 will remain constant at each time point, unless they experience a greater than 10% change in body weight. |
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Number of adverse events
Zeitfenster: Up to day 270
|
Up to day 270
|
|
Immunologic (CD8+ T cell and T regulatory cell (Treg) infiltration)
Zeitfenster: Up to day 43
|
• Estimate the effect of SBRT, CDX-1127 and the combination of SBRT and CDX- 1127 on CD8+ T cell and T regulatory cell (Treg) infiltration in prostate tumors.
|
Up to day 43
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Immunologic (lymphocyte composition of blood over time).
Zeitfenster: Up to day 270
|
• Estimate the effect of SBRT, CDX-1127, and the combination of SBRT and CDX-1127 on the lymphocyte composition of blood over time.
|
Up to day 270
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: James Larner, MD, University of Virginia
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 17456
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Prostataneoplasmen
-
John MascarenhasNational Cancer Institute (NCI); National Institutes of Health (NIH); Celgene... und andere MitarbeiterAbgeschlossenIDH2-Mutation | Accelerated/Blast-phase Myeloproliferative Neoplasm | Myelofibrose in der chronischen PhaseVereinigte Staaten, Kanada
Klinische Studien zur CDX1127
-
National Cancer Institute (NCI)Aktiv, nicht rekrutierendPlasmablastisches Lymphom | Refraktäres B-Zell-Non-Hodgkin-Lymphom | Rezidivierendes B-Zell-Non-Hodgkin-Lymphom | Wiederkehrendes diffuses großzelliges B-Zell-Lymphom | Refraktäres diffuses großzelliges B-Zell-Lymphom | Wiederkehrendes hochgradiges B-Zell-Lymphom mit MYC-, BCL2- und BCL6-Umlagerungen und andere BedingungenVereinigte Staaten
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)Aktiv, nicht rekrutierendRefraktäres nicht-kleinzelliges Lungenkarzinom | Lungenkrebs im Stadium IV AJCC v8Vereinigte Staaten
-
National Cancer Institute (NCI)Aktiv, nicht rekrutierendRezidivierendes Gallenblasenkarzinom | Metastasierendes Gallenblasenkarzinom | Stadium IV Gallenblasenkrebs AJCC v8 | Stadium IV Intrahepatisches Cholangiokarzinom AJCC v8 | Distaler Gallengangskrebs im Stadium IV AJCC v8 | Metastasierendes intrahepatisches Cholangiokarzinom | Rezidivierendes... und andere BedingungenVereinigte Staaten